Screener
Citius Oncology, Inc. CTOR Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Citius Oncology, Inc.’s 10-Q, filed August 14, 2026. Open the filing →
- Filed
- Aug 14, 2026, 4:35 PM EDT
- Fiscal quarter
- Q3 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001213900-26-090184
FAQ
- What is Citius Oncology, Inc.'s net income?
- Citius Oncology, Inc. (CTOR) reported net income of -$8.92M in Q2 2026.
- How has Citius Oncology, Inc.'s net income changed year-over-year?
- Citius Oncology, Inc.'s net income decreased by 66.2% year-over-year, from -$5.37M to -$8.92M.
- What is the long-term trend for Citius Oncology, Inc.'s net income?
- Over 2 years (2023 to 2025), Citius Oncology, Inc.'s net income has grown at a 39.6% compound annual growth rate (CAGR), from -$12.7M to -$24.76M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Citius Oncology, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude